Business Context and Reporting Period
Integra LifeSciences Holdings Corporation filed its unaudited Form 10-Q for the quarter and six months ended June 30, 2012. Integra develops and sells medical devices focused on neurosurgery, orthopedics, extremity reconstruction, spine and orthobiologics, regenerative medicine, and surgical instruments. Reportable segments were U.S. Neurosurgery, U.S. Instruments, U.S. Extremities, U.S. Spine and Other, and International.
Key Financial Metrics
| Metric | Three months ended June 30, 2012 | Three months ended June 30, 2011 | Six months ended June 30, 2012 | Six months ended June 30, 2011 |
|---|---|---|---|---|
| Revenue | $210.2 million | $193.3 million | $406.4 million | $374.4 million |
| Gross profit | $131.9 million | $120.5 million | $253.4 million | $236.6 million |
| Gross margin | 62.8% | 62.3% | 62.4% | 63.2% |
| Operating income | $18.0 million | $8.0 million | $35.5 million | $28.9 million |
| Net income | $8.5 million | $0.7 million | $15.2 million | $12.2 million |
| Diluted earnings per share | $0.30 | $0.02 | $0.53 | $0.40 |
| Operating cash flow | Not separately provided | Not separately provided | $34.6 million | $45.8 million |
Second-quarter operating margin was approximately 8.6%, compared with approximately 4.1% in the prior-year quarter. First-half operating margin was approximately 8.7%, compared with approximately 7.7% in the prior-year period.
- June 30, 2012 cash and cash equivalents were $75.5 million, compared with $100.8 million at December 31, 2011.
- Short-term investments were $39.3 million, all held by non-U.S. subsidiaries; total cash and short-term investments were approximately $114.8 million.
- Working capital was $365.1 million, compared with $350.4 million at year-end 2011.
- Senior Credit Facility borrowings were $321.9 million at a weighted-average rate of 1.8%, with approximately $278.1 million available. The facility matures in June 2016.
- The carrying amount of the 1.625% 2016 Convertible Senior Notes was $194.1 million, with $230.0 million principal outstanding.
- Total liabilities were $654.6 million and stockholders’ equity was $507.2 million at June 30, 2012.
Material Changes Versus the Prior Comparable Period
- Revenue increased 9% in both the quarter and first half. U.S. revenue increased 13% in the quarter and 12% year to date, while international revenue declined 4% and 2%, respectively, partly because of unfavorable foreign exchange.
- Orthopedics revenue increased 17% in the quarter and 18% year to date, supported by Ascension, regenerative medicine, extremities, and orthobiologics products. Neurosurgery revenue was approximately flat in the quarter and increased 0.4% year to date. Instruments revenue increased 7% in the quarter and 4% year to date.
- U.S. Extremities revenue increased 38% in the quarter and 32% year to date; U.S. Spine and Other increased 13% and 16%, respectively. International segment revenue decreased 4% in the quarter and 2% year to date.
- Net income improved substantially in the quarter primarily because the prior-year period included $8.4 million of additional stock-based compensation related to the former chief executive officer’s employment agreement. First-half net income also benefited from the absence of this charge.
- Gross margin improved in the quarter but declined year to date because of Plainsboro remediation costs, discontinued-product write-offs, and amortization of inventory fair-value step-ups related to the SeaSpine and Ascension acquisitions.
- Interest expense increased to $7.1 million in the quarter and $15.0 million year to date, partly because of the 2016 Notes, the interest-rate swap, and higher non-cash convertible-debt interest.
- Cash flow from operations declined year to date, primarily because approximately $31.0 million of accreted interest paid in connection with repayment of the 2012 Notes was classified as an operating cash outflow.
Guidance, Outlook, Risks, and Unusual Items
- Management expected 2012 consolidated gross margin to be flat to slightly higher than 2011 and targeted research and development spending at 6% to 7% of revenue.
- Management expected a full-year effective tax rate of approximately 21.3%, subject to revision as uncertain tax positions reverse or are resolved.
- Management expected Plainsboro production to return to normal levels in the fourth quarter of 2012. It anticipated approximately $0.7 million of additional remediation-related expense and $2.5 million to $3.0 million of additional capital investment during the remainder of 2012.
- The company planned $30 million to $40 million of second-half capital expenditures, primarily for regenerative medicine capacity, the enterprise resource planning system, and orthopedic instrument sets.
- The FDA issued a December 2011 warning letter concerning quality-system and compliance issues at the Plainsboro regenerative medicine facility. A June-July 2012 inspection resulted in seven Form 483 observations, including a repeat observation related to corrective and preventive actions. The warning letter did not restrict manufacturing or shipment and did not require a product recall, but the FDA stated that certain exportation certificates and PMA approvals could remain restricted until remediation is completed.
- Product shortages related to the Plainsboro remediation caused backorders; most, but not all, had been cleared by the filing date.
- The company reported ordinary-course litigation and contingencies that management did not expect to have a material adverse effect in the aggregate, while noting that particular matters could materially affect a period. The U.S. Attorney’s Office for the District of New Jersey contacted the company regarding alleged fabricated invoices or surgeries involving two sales representatives. Integra stated it was cooperating voluntarily and was not a subject or target at that time.
- Goodwill allocated to the U.S. Spine business had an estimated fair-value cushion of approximately 15% at January 1, 2012, with $31.7 million of allocated goodwill; a decline in fair value could result in an impairment charge.
- On June 7, 2012, Executive Chairman Stuart Essig ceased being an employee but remained chairman and a director. Approximately 1.67 million deferred stock units were expected to be distributed in shares, with related tax withholding expected in the fourth quarter.
Most Important Facts for Investors to Verify
- Progress and FDA acceptance of remediation at the Plainsboro facility, including resolution of the repeat CAPA observation and restoration of normal production and exportation approvals.
- Whether the expected fourth-quarter production recovery and related revenue realization occur, particularly for regenerative medicine products.
- Actual second-half remediation costs, capital expenditures, and the effect on gross margin and operating cash flow.
- Leverage and liquidity after repayment of the 2012 Notes, including borrowing capacity and compliance with the Senior Credit Facility covenants.
- Resolution and cash impact of uncertain tax positions, including the anticipated reversal supporting the approximately 21.3% full-year tax-rate estimate.
- Potential impact of the U.S. Attorney inquiry, ordinary-course litigation, regulatory compliance matters, and any future FDA enforcement action.
- Foreign exchange effects and European demand, which reduced international revenue during the reporting period.